Pimecrolimus (Elidel, SDZ ASM 981) is an anti-inflammatory and immunomodulatory 33-epichloro-derivative of macrolactam ascomycin, with low potential for affecting systemic immune responses compared with other calcineurin inhibitors, cyclosporin A and tacrolimus. Despite numerous studies focused on the mechanism of pimecrolimus action on mast cells, only the single report has addressed pimecrolimus effects on other typical FcεRI-expressing cells, the basophils. Patients allergic to birch pollen (n = 20), hymenopteran venoms (n = 23) and 10 non-allergic volunteers were examined. Primary human basophils pre-treated or not with 0.5-50 μMol pimecrolimus were exposed to various concentrations of recombinant Bet v 1a allergen, bee or wasp venom extracts and anti-IgE for 20 min, and then examined for the expression of CD45, CD193, CD203c, CD63 and CD164 using flow cytometry. The externalization of basophil activation markers (CD63 and CD164) was equally inhibited through pimecrolimus in cells activated by recombinant pollen allergen, hymenopteran venom extracts and anti-IgE. Although the individual response rate was subject to strong variation, importantly, pre-treatment with pimecrolimus lowered the number of activated basophils in response to any of the stimuli in the basophils from all patients. The inhibition was concentration-dependent; approximately half of the basophils were inhibited in the presence of 2.5 mMol pimecrolimus. Pimecrolimus is a valuable new tool for the inhibition of hyper-reactive basophils in patients with pollen allergy and a history of anaphylactic reactions to bee or wasp venoms. Further research should address short-term use of pimecrolimus in vivo in a wide spectrum of allergic diseases.

2nd Department of Internal Medicine 3rd Faculty of Medicine Charles University Prague Prague Czech Republic

Department of Immunology 3rd Faculty of Medicine Charles University Prague Prague Czech Republic

Zobrazit více v PubMed

Arbes SJ, Gergen PJ, Elliott L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: Results from the Third National health and Nutrition Examination Survey. J Allergy Clin Immunol 2005;116: 377–383. PubMed

Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy 2004;34: 520–526. PubMed

Department of Health. Prescription statistics. Available: http://webarchive.nationalarchives.gov.uk/ 20040117115633/http:/www.doh.gov.uk/prescriptionstatistics/index.htm. Accessed 7 April 2015.

D`Amato G, Cecchi L, Bonini S, Nunes C, Annesi-Maesano I, Behrendt H, et al. Allergenic pollen and pollen allergy in Europe. Allergy 2007;62: 976–990. PubMed

Eriksson NE, Holmen A. Skin prick test with standardized extracts of inhalant allergens in 7099 adult patients with asthma or rhinitis cross-sensitizations and relationship to age, sex, month of birth and year of testing. J Investig Allergol Clin Immunol 1996;6: 36–46. PubMed

Fernandez J, Blanca M, Soriano V, Sanchez J, Juarez C. Epidemiological study of the prevalence of allergic reactions to Hymenoptera in a rural population in the Mediterranean area. Clin Exp Allergy 1999;29: 1069–1074. PubMed

Settipane GA, Boyd GK. Prevalence of bee sting allergy in 4,992 boy scouts. Acta Allergol 1970;25: 286–291. PubMed

Biló BM, Rueff F, Mosbech H, Bonifazi F, Oude-Elberink JNG, EAACI Interest Group on Insect Venom Hypersensitivity. Diagnosis of Hymenoptera venom allergy. Allergy 2005;60: 1339–1349. PubMed

Golden DB, Marsh DG, Kagey-Sobotka A, Freidhoff L, Szklo M, Valentine MD, et al. Epidemiology of insect venom sensitivity. JAMA 1989;262: 240–244. PubMed

Herbert FA, Salkie ML. Sensitivity to hymenoptera in adult males. Ann Allergy 1982;48: 12–13. PubMed

Moneret-Vautrin DA, Morisset M, Flabbee J, Beaudouin E, Kanny G. Epidemiology of life-threatening and lethal anaphylaxis: a review. Allergy 2005;60: 443–451. PubMed

Weissenbacher S, Traidl-Hoffmann C, Eyerich K, Katzer K, Braeutigam M, Loeffler H, et al. Modulation of atopy patch test and skin prick test by pretreatment with 1% pimecrolimus cream. Int Arch Allergy Immunol 2006;140: 239–244. PubMed

Kalthoff ES, Chung J, Musser P, Stuetz A. Pimecrolimus does not affect the differentiation, maturation and function of human monocyte-derived dendritic cells, in contrast to corticosteroids. Clin Exp Immunol 2003;133: 350–359. PubMed PMC

Ma Z, Tovar JP, Kwong KY, Paek D. Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis. Int Arch Allergy Immunol 2010;153: 413–418. 10.1159/000316353 PubMed DOI

Grattan CE, O`Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000;143: 365–372. PubMed

Hultsch T, Muller KD, Meingassner JG, Grassberger M, Schopf RE, Knop J. Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Dermatol Res 1998;290: 501–507. PubMed

Grassberger M, Baumruker T, Enz A, Hiestand P, Hultsch T, Kalthoff F, et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999;141: 264–273. PubMed

Stuetz A, Grassberger M, Meingassner JG. Pimecrolimus (Elidel, SDZ ASM 981)—preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg 2001;20: 233–241. PubMed

Zuberbier T, Chong S-U, Grunow K, Guhl S, Welker P, Grassberger M, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001;108: 275–280. PubMed

Wolanczyk-Medrala A, Barg W, Liebhart J, Panaszek B, Nadobna G, Litwa M, et al. Validation of basophil CD164 upregulation for pollen allergy diagnosis. Arch Immunol Ther Exp (Warsz) 2010;58: 459–465. PubMed

Knol EF, Mul RP, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol 1991;88: 328–338. PubMed

Wolanczyk-Medrala A, Barg W, Medrala W. CD164 as a basophil activation marker. Curr Pharm Des 2011;17: 3786–3796. PubMed

Hausmann OV, Gentinetta T, Fux M, Ducrest S, Pichler WJ, Dahinden CA. Robust expression of CCR3 as a single basophil selection marker in flow cytometry. Allergy 2011;66: 85–91. 10.1111/j.1398-9995.2010.02431.x PubMed DOI

Sturm GJ, Kranzelbinder B, Sturm EM, Heinemann A, Groselj-Strele A, Aberer W. The basophil activation test in the diagnosis of allergy: Technical issues and critical factors. Allergy 2009;64: 1319–1326. 10.1111/j.1398-9995.2009.02004.x PubMed DOI

Sakai M, Miyake H, Tashiro S, Okumura Y, Kido H. Inhibitory effect of FK506 and cyclosporin A on the growth and invasion of human liver cancer cells. J Med Invest 2004;51: 63–69. PubMed

Novartis Pharma GmbH. Elidel. Available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2004/21302s005lbl.pdf. Accessed 7 April 2015.

Lerche CM, Philipsen PA, Poulsen T, Wulf HC. Topical pimecrolimus and tacrolimus do not accelerate photocarcinogenesis in hairless mice after UVA or simulated solar radiation. Exp Dermatol 2009;18: 246–251. 10.1111/j.1600-0625.2008.00812.x PubMed DOI

Doelker L, Tran C, Gkomouzas A, Grand D, Sorg O, Saurat JH, et al. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients. Exp Dermatol 2006;15: 342–346. PubMed

Arellano FM, Wentworth CE, Arana A, Fernandez C, Paul CF. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007;127: 808–816. PubMed

Luger T, Boguniewicz M, Carr W, Cork M, Deleuran M, Eichenfield L, et al. Pimecrolimus in atopic dermatitis: Consensus on safety and the need to allow use in infants. Pediatr Allergy Immunol 2015;26: 306–315. 10.1111/pai.12331 PubMed DOI PMC

Compton SJ, Cairns JA, Holgate ST, Walls AF. The role of mast cell tryptase in regulating endothelial cell proliferation, cytokine release, and adhesion molecule expression: tryptase induces expression of mRNA for IL-1ß and IL-8 and stimulates the selective release of IL-8 from human umbilical vein endothelial cells. J Immunol 1998;161: 1939–1946. PubMed

Monneret G. CCR3 for basophil activation test: A necessary but insufficient step. Clin Exp Allergy 2010;40: 953 10.1111/j.1365-2222.2010.03516.x PubMed DOI

Chirumbolo S, Ortolani R, Vella A. CCR3 as a single selection marker compared to CD123/HLADR to isolate basophils in flow cytometry: some comments. Cytometry A 2011;79: 102–106. 10.1002/cyto.a.21008 PubMed DOI

Chirumbolo S. Basophil activation test in allergy: Time for an update? Int Arch Allergy Immunol 2012;158: 99–114. 10.1159/000331312 PubMed DOI

Hauswirth AW, Natter S, Ghannadan M, Majlesi Y, Schernthaner GH, Sperr WR, et al. Recombinant allergens promote expression of CD203c on basophils in sensitized individuals. J Allergy Clin Immunol 2002;110: 102–109. PubMed